List of Contents

Psoriasis Treatment Market Size, Share, and Trends 2024 to 2034

The global psoriasis treatment market size was USD 29.27 billion in 2023, calculated at USD 31.61 billion in 2024 and is expected to reach around USD 68.24 billion by 2034, expanding at a CAGR of 8% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 2034
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Psoriasis Treatment Market 

5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Psoriasis Treatment Market, By Drug Class

8.1. Psoriasis Treatment Market, by Drug Class, 2024-2034

8.1.1. Interleukins

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. TNF Inhibitors

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Psoriasis Treatment Market, By Treatment Type

9.1. Psoriasis Treatment Market, by Treatment Type, 2024-2034

9.1.1. Biologic Drugs

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Small Molecule Systemic Drugs

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Tropical Therapies

9.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Psoriasis Treatment Market, By Type 

10.1. Psoriasis Treatment Market, by Type, 2024-2034

10.1.1. Psoriatic Arthritis

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Plaque Psoriasis

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Psoriasis Treatment Market, By Route of Administration

11.1. Psoriasis Treatment Market, by Route of Administration, 2024-2034

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Parenteral

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Topical

11.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Psoriasis Treatment Market, By Distribution Channel

12.1. Psoriasis Treatment Market, by Distribution Channel, 2024-2034

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Forecast (2021-2034)

12.1.2. Online pharmacies

12.1.2.1. Market Revenue and Forecast (2021-2034)

12.1.3. Retail Pharmacies

12.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 13. Global Psoriasis Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.1.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.1.3. Market Revenue and Forecast, by Type (2021-2034)

13.1.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.1.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.1.6.3. Market Revenue and Forecast, by Type (2021-2034)

13.1.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.1.7.  Rest of North America

13.1.7.1.  Market Revenue and Forecast, by Drug Class (2021-2034)

13.1.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.1.7.3. Market Revenue and Forecast, by Type (2021-2034)

13.1.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.2.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.2.3. Market Revenue and Forecast, by Type (2021-2034)

13.2.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.2.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.2.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.2.6.3. Market Revenue and Forecast, by Type (2021-2034)

13.2.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.2.7.  Germany

13.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.2.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.2.7.3.  Market Revenue and Forecast, by Type (2021-2034)

13.2.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.2.8.  France

13.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.2.8.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.2.8.3. Market Revenue and Forecast, by Type (2021-2034)

13.2.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.2.8.5.  Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.2.9. Rest of Europe

13.2.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.2.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.2.9.3. Market Revenue and Forecast, by Type (2021-2034)

13.2.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.2.9.5.  Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.3.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.3.3. Market Revenue and Forecast, by Type (2021-2034)

13.3.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.3.6.  India

13.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.3.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.3.6.3. Market Revenue and Forecast, by Type (2021-2034)

13.3.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.3.7. China

13.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.3.7.2.  Market Revenue and Forecast, by Treatment Type (2021-2034)

13.3.7.3. Market Revenue and Forecast, by Type (2021-2034)

13.3.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.3.8. Japan

13.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.3.8.2.  Market Revenue and Forecast, by Treatment Type (2021-2034)

13.3.8.3. Market Revenue and Forecast, by Type (2021-2034)

13.3.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.3.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.3.9.3. Market Revenue and Forecast, by Type (2021-2034)

13.3.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.4.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.4.3. Market Revenue and Forecast, by Type (2021-2034)

13.4.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.4.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.4.6.3.  Market Revenue and Forecast, by Type (2021-2034)

13.4.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.4.7. North Africa

13.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.4.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.4.7.3. Market Revenue and Forecast, by Type (2021-2034)

13.4.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.4.8. South Africa

13.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.4.8.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.4.8.3. Market Revenue and Forecast, by Type (2021-2034)

13.4.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.4.9. Rest of MEA

13.4.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.4.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.4.9.3. Market Revenue and Forecast, by Type (2021-2034)

13.4.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.5.  Latin America

13.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.5.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.5.3. Market Revenue and Forecast, by Type (2021-2034)

13.5.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.5.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.5.6.3. Market Revenue and Forecast, by Type (2021-2034)

13.5.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

13.5.7. Rest of LATAM

13.5.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

13.5.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)

13.5.7.3. Market Revenue and Forecast, by Type (2021-2034)

13.5.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)

13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)

Chapter 14. Company Profiles

14.1. Johnson & Johnson Services, Inc. (U.S.)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Pfizer Inc. (U.S.)

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. AbbVie Inc. (U.S.)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Novartis AG (Switzerland)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. LEO Pharma A/S (Denmark)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc. (U.S.)

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. UCB S.A. (Belgium)

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Sun Pharmaceutical Industries Ltd. (India)

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Amgen Inc. (U.S.)

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Eli Lilly and Company (U.S.)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global psoriasis treatment market size was accounted at USD 29.27 billion in 2023 and is expected to reach around USD 68.24 billion by 2034.

The global psoriasis treatment market is poised to grow at a CAGR of 8% from 2014 to 2034.

The major players operating in the psoriasis treatment market are Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), LEO Pharma A/S (Denmark), Merck & Co., Inc. (U.S.), UCB S.A. (Belgium), Sun Pharmaceutical Industries Ltd. (India), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), Evelo Biosciences, Inc. (U.S.)

The rapidly increasing number of patients of psoriasis has helped to increase the demand for its treatment.

North America region will lead the global psoriasis treatment market during the forecast period 2024 to 2034.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us